HAE NYSE Week ended 31 Jul 2026

Weekly Investor Report

Haemonetics Corporation · Healthcare · Medical Devices

Open interactive chart View report data
Latest close 85.54 USD
8.6% latest week
Weekly setup

Constructive, but selective

The weekly trend is active. Price is 28.2% above the Trend Line and sits at 95.6% of its 52-week range. The latest completed week returned 8.6%, after a 13.9% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks weakly; valuation is expensive relative to peers. Options positioning is volatility with 48/100 conviction, while the latest news-sentiment score is 56/100. Near-term considerations: price is close to its 52-week high; volume confirmation is below normal; earnings are due in 4d.

Setup score 58 out of 100
Latest Close 85.54 USD 31 Jul 2026
1W Return 8.6% latest completed week
4W Return 13.9% short-term follow-through
12W Return 55.2% quarterly tape
Trend Breadth 23.1% 12 of 52 weeks active
Volume Ratio 0.9x vs 13-week average
What is working
  • The trend backdrop is active with a 3-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • Next-week expectancy is negative at 43.98% based on similar historical setup states.
What to watch next
  • Price is close to its 52-week high; watch for continuation or exhaustion.
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 8.6% Latest completed week; four-week move 13.9%. Indicator stack 23/66 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 43.98% Historical one-week expectancy contributes to the evidence score when direction is confirmed. Options pressure Volatility 48/100 conviction; expected move 12.6%. News sentiment 56/100 61 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 28.2% above the Trend Line and sits at 95.6% of its 52-week range. The latest completed week returned 8.6%, after a 13.9% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.7312-week average 0.32

12-week confirmation

Trend active3/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure11/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership8/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.73Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 13.9% over four weeks, 55.2% over 12 weeks, and 14.4% over one year. The current trend has remained active for 3 consecutive weeks.

Performance by holding period

1W8.6%
4W13.9%
12W55.2%
26W28.3%
52W14.4%
Active trend streak3 weeks
Active weeks in one year12
Trend breadth23.1%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.92Latest activity-pressure read.
Pressure change-13.6%Four-week change in activity pressure.
Leadership21.07Latest relative-leadership reading.
RS change288.3%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks weakly; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 94% Model confidence 90%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength24/100Blend of value, momentum, and quality. Underlying universe rank 77; rank 1 is best.
Value19/100Relative valuation strength. Underlying universe rank 82; rank 1 is best.
Quality85/100Profitability and accounting quality. Underlying universe rank 16; rank 1 is best.
Momentum30/100Medium-term price momentum. Underlying universe rank 71; rank 1 is best.
Growth4/100Revenue and earnings growth. Underlying universe rank 97; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework29/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
36.8x
Price divided by trailing earnings.
Price / sales
2.7x
Market value relative to trailing revenue.
EV / EBITDA
16.3x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
7.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
57.3%
Gross profit retained from each unit of revenue.
Operating margin
12.6%
Operating profit retained from revenue.
Free-cash-flow margin
24.4%
Free cash flow generated from revenue.
Return on invested capital
7.2%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-2.0%
Latest one-year revenue growth.
EPS growth
-42.0%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
47.5%
Latest one-year free-cash-flow growth.
Piotroski F-score
6/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
4.8%
Net share repurchases relative to market value.
Shareholder yield
4.8%
Dividend yield plus net buyback yield.
Net debt / EBITDA
3.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

HAE shows volatility options pressure with a 48/100 conviction score, put-call volume ratio of 0.25, expected move of 12.6%, and Sharemaestro trend signal active.

Conviction48/100
Expected move12.6%
Put/call volume0.25
Pressure70
Speculation8
Volatility87
Trend agreement31
Open options detail
Insider activity7 / 10

7 acquisitions and 10 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment56/100

Weighted news tone is neutral across 61 relevant articles.

17 positive · 42 neutral · 2 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move12.6%Nearest-chain priced movement where available.
52-week drawdown-2.0%Distance below the 52-week high.
13-week volatility6.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher16 of 2610 weeks finished lower.
Best week+16.3%Week of 22 May.
Worst week-11.0%Week of 6 Feb.
Latest week+8.6%Week of 31 Jul.

Shape of recent returns

Strong gains8
Modest gains8
Flat weeks0
Modest losses5
Sharp losses5
Recent vol6.0%13-week weekly-return volatility.
Base vol8.2%52-week weekly-return volatility.
Up/down split27/25Count of positive and negative weeks in the 52-week window.
Average skew5.7% / -4.9%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape51/100

Trend, activity pressure, participation, and risk combine to a 51/100 tape read.

 Indicator analysis60/100

Latest 12-week confirmation: trend 3/12, activity pressure 11/12, relative leadership 8/12.

Activity pressure 0.73; No reversal markers Next-Week ExpectancyNegative 43.98%

Next-week expectancy is negative with a 43.98% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors39/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 12; Small Cap Core rank 76 SVQF29/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 719.0 of 1013 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options43/100

HAE shows volatility options pressure with a 48/100 conviction score, put-call volume ratio of 0.25, expected move of 12.6%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 12.6% Sentiment56/100

Weighted news tone is neutral across 61 relevant articles.

Earnings Preview: Haemonetics (HAE) Q1 Earnings Expected to Decline Insiders7 / 10

7 acquisitions and 10 disposals in the latest 180-day insider tape.

 Earnings4d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202685.54 USD8.6%66.73 USD74.33 USD0.9221.073.8MOn
24 Jul 202678.78 USD1.2%66.55 USD74.36 USD0.8212.562.4MOn
17 Jul 202677.86 USD2.2%66.60 USD74.45 USD0.9110.313.3MOn
10 Jul 202676.19 USD1.5%66.68 USD74.55 USD0.926.022.6MOff
3 Jul 202675.07 USD-2.9%66.92 USD74.60 USD1.075.433.1MOff
26 Jun 202677.29 USD4.2%67.22 USD74.65 USD1.0910.374.7MOff
19 Jun 202674.17 USD-5.2%67.35 USD74.70 USD1.003.084.3MOff
12 Jun 202678.20 USD9.7%67.50 USD74.77 USD0.949.227.2MOff
5 Jun 202671.28 USD5.1%67.35 USD74.81 USD0.62-0.144.2MOff
29 May 202667.81 USD3.5%67.25 USD74.91 USD0.36-7.794.1MOff
22 May 202665.49 USD16.3%66.66 USD75.04 USD0.05-10.124.4MOff
15 May 202656.29 USD2.1%66.18 USD75.16 USD-0.22-22.495.1MOff
8 May 202655.12 USD-7.0%65.98 USD75.34 USD-0.39-24.585.8MOff
1 May 202659.26 USD-1.1%65.77 USD75.56 USD-0.59-17.772.8MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.